《大行報告》麥格理首予康方生物(09926.HK)「跑贏大市」評級 目標價49元
麥格理發表報告指出,康方生物(09926.HK)利用其研究技能(特別是雙特異性平台)作自主研發,並良好地設計和執行臨床試驗,是內地少數頂級生物製藥公司之一。
該行認為,儘管康方生物的銷售團隊規模不大,但其開坦尼(Cadonilimab)在中國的銷售強勁,該行料開坦尼經風險調整後銷售峰值約47億元人民幣。此外,公司的依沃西(Ivonescimab)有潛力作為肺癌治療適應症突破性治療藥物,該領域在全球利潤豐厚。
此外,該行首予康方生物「跑贏大市」評級,目標價49元,預期公司應有足夠的現金營運業務,相信可於2027年實現盈利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.